Stockscreener 앱 받기
1.265
2.30%
0.015
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Lineage Cell Therapeutics joins panel on novel treatments at Clinical Trials at the Summit - Traders Union
Lineage Cell Shareholders Reaffirm Governance and Executive Pay - TipRanks
Lineage Cell (NYSE: LCTX) investors back board, say-on-pay as OPC1 grant bid withdrawn - Stock Titan
LCTX Q1 2026 Earnings: EPS Miss Reflects Ongoing R&D InvestmentTrough Earnings Signal - newsline.com
LCTX Q1 2026 Earnings: EPS Misses Estimates by 47% as Company Continues Clinical DevelopmentReturn On Assets - newsline.com
How The Lineage Cell Therapeutics (LCTX) Story Is Shifting With New Data And Analyst Targets - Yahoo Finance
LCTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lineage Cell Therapeutics (LCTX) price target increased by 14.58% to 5.61 - MSN
LCTX Q1 2026 Earnings: Wider Loss Than Expected Amid Ongoing Pipeline DevelopmentForward EPS Estimate - newsline.com
LCTX Q1 2026 Earnings: Missed Estimates as R&D Spending Weighs on Bottom LineHealthcare Earnings Report - The Legal Advocate
Lineage Cell Therapeutics (LCTX) Gains 3% as Biotech Sector Finds SupportNHNL Ratio - The Legal Advocate
Lineage Cell Therapeutics Inc. (LCTX) Q1 2026 Earnings: EPS Misses Estimates Amid Pipeline Progress, Stock Rises 3.08%Annual Earnings Summary - The Legal Advocate
Lineage Cell Therapeutics spotlights CEO participation in fireside chat with HCWCO at BioConnect - Traders Union
Lineage Cell Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Continues Pipeline InvestmentEstimate Accuracy - newsline.com
Promising Penny Stocks To Consider In May 2026 - simplywall.st
Lineage Cell Therapeutics Inc. (LCTX) Q1 2026 Earnings: Miss on EPS as Clinical-Stage Biotech Continues DevelopmentROA Comparison - newsline.com
Lineage Cell Therapeutics (LCTX) Slides 1.52% – Testing Key Support Near $1.23Fear Greed Extreme - newsline.com
LCTX Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Reports No Revenue - The Legal Advocate
Lineage reports positive 36-month findings on GA cell therapy - Eyes On Eyecare
Earnings Preview: LCTX to Report Financial Results Post-market on May 12 - Moomoo
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Investing News Network
Lineage Cell Therapeutics, Inc. Common Stock (NY: LCTX - FinancialContent
Lineage Cell Therapeutics, Inc. Common Stock (NYSE:LCTX) Stock Quote - FinancialContent
Lineage Cell Therapeutics Q1 Earnings Call Highlights - sharewise.com
Lineage Cell Therapeutics Q1 2026 earnings preview - MSN
Lineage Cell Therapeutics featured in European Pharmaceutical Review report on scalable cell therapies - Traders Union
Lineage Cell Therapeutics (LCTX) Returns To Loss In Q1 2026 Challenging Profitability Narratives - Sahm
Lineage Cell Therapeutics Highlights R&D Momentum Amid Losses - TipRanks
Q1 2026 Lineage Cell Therapeutics Inc Earnings Call Transcript - GuruFocus
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2026 Earnings Call Transcript - Insider Monkey
Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing - MSN
Lineage Cell (LCTX) reports Q1 loss, lags revenue estimates - MSN
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Lineage Cell Therapeutics (LCTX) Reports Q1 2026 Earnings and St - GuruFocus
TradingKey - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highl - GuruFocus
Lineage Cell Therapeutics (LCTX) Reports Q1 Results and Advancem - GuruFocus
Is Lineage Cell Therapeutics (LCTX) Overvalued After Q1 2026 EPS - GuruFocus
Lineage Cell (LCTX) Receives Funding to Support Operations Throu - GuruFocus
LCTX: Pipeline expansion, manufacturing progress, and strong cash runway drive 2026 outlook - TradingView
LCTX: Strong pipeline expansion and robust cash position support continued clinical and manufacturing progress - TradingView
4.93%
0.20%
자본화:
|
볼륨(24시간):